Vasomune Therapeutics is a private biotechnology company developing the next generation of medicine. Our innovative approach focuses on combating vascular dysfunction and defending against illness by modifying the body’s cellular response to disease. Our company’s lead drug candidate targets a signaling molecule responsible for regulating the vascular response to injury (vascular leak) which is associated with a wide range of diseases such as Acute Respiratory Distress Syndrome (ARDS), Acute Kidney Injury, Diabetic Retinopathy and Cardiopulmonary Bypass. Through pioneering the fight against vascular leak and by decreasing the activity of multiple proinflammatory factors, we can greatly increase the chances of patient health and success. For more, visit www.vasomune.com